VIRAGEN
Viragen, together with its subsidiaries, engages in the research, development, manufacture, and commercialization of therapeutic proteins for the treatment of cancers and viral diseases in humans. Its product and product candidate portfolio includes Multiferon, a human alpha interferon product that comprise multiple subtype alpha interferons for the treatment of various infectious diseases and cancers; VG101 a therapeutic humanized monoclonal antibody targeting the treatment of malignant melanom... a; and VG102 a therapeutic humanized antibody designed for the treatment of various solid tumors. The company also develops Avian Transgenics technology for production of human therapeutic proteins and antibodies. It operates in the United States, Scotland, and Sweden. The company was founded in 1979 and is headquartered in Plantation, Florida.
VIRAGEN
Industry:
Biotechnology Manufacturing Therapeutics
Founded:
1979-01-01
Address:
Fort Lauderdale, Florida, United States
Country:
United States
Status:
Active
Total Funding:
9.43 M USD
Similar Organizations
Anika Therapeutics
Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its
Investors List
RAB Capital
RAB Capital investment in Venture Round - Viragen
PEF Advisors
PEF Advisors investment in Venture Round - Viragen